z-logo
open-access-imgOpen Access
Reprogramming in vivo produces teratomas and iPS cells with totipotency features
Author(s) -
María Abad,
Lluc Mosteiro,
Cristina Pantoja,
Marta Cañamero,
Teresa Rayón,
Inmaculada Ors,
Osvaldo GrañaCastro,
Diego Megı́as,
Orlando Domı́nguez,
Dolores Martínez,
Miguel Manzanares,
Sagrario Ortega,
Manuel Serrano
Publication year - 2013
Publication title -
nature
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 15.993
H-Index - 1226
eISSN - 1476-4687
pISSN - 0028-0836
DOI - 10.1038/nature12586
Subject(s) - reprogramming , sox2 , biology , induced pluripotent stem cell , klf4 , embryonic stem cell , microbiology and biotechnology , homeobox protein nanog , stem cell , in vivo , haematopoiesis , regenerative medicine , cell , genetics , gene
Reprogramming of adult cells to generate induced pluripotent stem cells (iPS cells) has opened new therapeutic opportunities; however, little is known about the possibility of in vivo reprogramming within tissues. Here we show that transitory induction of the four factors Oct4, Sox2, Klf4 and c-Myc in mice results in teratomas emerging from multiple organs, implying that full reprogramming can occur in vivo. Analyses of the stomach, intestine, pancreas and kidney reveal groups of dedifferentiated cells that express the pluripotency marker NANOG, indicative of in situ reprogramming. By bone marrow transplantation, we demonstrate that haematopoietic cells can also be reprogrammed in vivo. Notably, reprogrammable mice present circulating iPS cells in the blood and, at the transcriptome level, these in vivo generated iPS cells are closer to embryonic stem cells (ES cells) than standard in vitro generated iPS cells. Moreover, in vivo iPS cells efficiently contribute to the trophectoderm lineage, suggesting that they achieve a more plastic or primitive state than ES cells. Finally, intraperitoneal injection of in vivo iPS cells generates embryo-like structures that express embryonic and extraembryonic markers. We conclude that reprogramming in vivo is feasible and confers totipotency features absent in standard iPS or ES cells. These discoveries could be relevant for future applications of reprogramming in regenerative medicine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom